Long-Term Outcome After Radical Prostatectomy for Patients With Lymph Node Positive Prostate Cancer in the Prostate Specific Antigen Era

Journal of Urology

Volumn 178, Issue 3, 2007, Pages 864-871

  Boorjian, Stephen A ^a   Thompson, R Houston ^a   Siddiqui, Sameer ^a   Bagniewski, Stephanie ^a   Bergstralh, Erik J ^a   Karnes, R Jeffrey ^a   Frank, Igor ^a   Blute, Michael L ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

lymph node dissection; prostate; prostate specific antigen; prostatectomy; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SEX HORMONE; STEROID; STRONTIUM;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; SURVIVAL RATE;

AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34547664611     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.048     Document Type: Article

References (20)

1. Han M., Partin A.W., Piantadosi S., Epstein J.I., and Walsh P.C. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 166 (2001) 416
2. Palapattu G.S., Allaf M.E., Trock B.J., Epstein J.I., and Walsh P.C. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol 172 (2004) 1860
3. Daneshmand S., Quek M.L., Stein J.P., Lieskovsky G., Cai J., Pinski J., et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172 (2004) 2252
4. Cheng L., Zincke H., Blute M.L., Bergstralh E.J., Scherer B., and Bostwick D.G. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91 (2001) 66
5. Bader P., Burkhard F.C., Markwalder R., and Studer U.E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J Urol 169 (2003) 849
6. Allaf M.E., Palapattu G.S., Trock B.J., Carter H.B., and Walsh P.C. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 172 (2004) 1840
7. Masterson T.A., Bianco Jr. F.J., Vickers A.J., DiBlasio C.J., Fearn P.A., Rabbani F., et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175 (2006) 1320
8. Cadeddu J.A., Partin A.W., Epstein J.I., and Walsh P.C. Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 50 (1997) 251
9. Ghavamian R., Bergstralh E.J., Blute M.L., Slezak J., and Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 161 (1999) 1223
10. Grimm M.O., Kamphausen S., Hugenschmidt H., Stephan-Odenthal M., Ackermann R., and Vogeli T.A. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 41 (2002) 628
11. Messing E.M., Manola J., Yao J., Kiernan M., Crawford D., Wilding G., et al. Immediate versus deferred androgen deprivation treatment in patients with node- positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472
12. Studer U.E., Whelan P., Albrecht W., Casselman J., de Reijke T., Hauri D., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 20891. J Clin Oncol 24 (2006) 1868
13. Frazier II H.A., Robertson J.E., and Paulson D.F. Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival. World J Urol 12 (1994) 308
14. Ferrari A.C., Stone N.N., and Eyler J.N. Prospective analysis of prostate-specific markers in pelvic lymph node of patients with high-risk prostate cancer. J Natl Cancer Inst 89 (1997) 1498
15. DiMarco D.S., Zincke H., Sebo T.J., Slezak J., Bergstralh E.J., and Blute M.L. The extent of lymphadenectomy for pTXN0 prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173 (2005) 1121
16. Isaacs J.T. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res 49 (1989) 6290
17. Sokoloff M.H., Rinker-Schaeffer C.W., Chung L.W.K., and Brendler C.B. Adjunctive therapy for men with high risk localized and locally advanced prostate cancer: targeting disseminated tumor cells. J Urol 172 (2004) 2539
18. Zincke H., Bergstralh E.J., Larson-Keller J.J., Farrow G.M., Myers R.P., Leiber M.M., et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: Evidence for favorable survival in patients with DNA diploid tumors. Cancer 70 (1992) 311
19. Heidenreich A., Varga Z., and von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167 (2002) 1681
20. Bochner B.H., Herr H.W., and Reuter V.E. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 166 (2001) 2295